Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases

Arthritis and Rheumatism
J de la MataJ J Gomez-Reino

Abstract

To determine the effects of short-term, maximum-tolerated-dose and long-term, optimum-dose iloprost treatment of severe pulmonary hypertension associated with systemic sclerosis (SSc) and the primary antiphospholipid syndrome (APS). Three patients with SSc and 2 with APS who had failed to respond to oral vasodilator therapy for pulmonary hypertension were enrolled in a 32-week, open, prospective trial. Short-term infusion of maximum-tolerated doses and continuous infusion of optimum doses of iloprost were carried out following baseline cardiac catheterization. Catheterization was repeated at 2 and 32 weeks. All 5 patients completed the study and continued therapy for an average of 82 weeks (range 58-103). Acute infusion of maximum tolerated doses significantly ameliorated the cardiac index (0.92 liters/minute/m2; P < 0.01), pulmonary artery O2 saturation (10.6%; P < 0.05), and pulmonary resistance (-6.7 units; P < 0.05). After 2 weeks of continuous infusion of optimum doses, there was improvement in pulmonary resistance (> or = 16%) and pulmonary artery O2 saturation (> 30%) in the 2 patients with primary APS. After 2 and 32 weeks, the 3 SSc patients showed variable hemodynamic responses. New York Heart Association functional c...Continue Reading

References

Jan 1, 1976·Medicine·L Axelrod
Jul 9, 1992·The New England Journal of Medicine·J Loscalzo
Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Dec 1, 1986·Journal of the American College of Cardiology·S RichB H Brundage
Nov 10, 1989·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·R OmdalW Hinderaker
Oct 1, 1989·Chest·J E McManigle, M F Tenholder
May 1, 1986·The New England Journal of Medicine·R CariouJ Caen
Sep 1, 1987·The American Review of Respiratory Disease·T Higenbottam
Feb 1, 1985·The American Journal of Medicine·J W ShuckJ T Tesar
Jul 1, 1970·The American Journal of Medicine·G WalcottA L Brown
May 1, 1982·Annals of Internal Medicine·M B KahalehE C Leroy
Oct 1, 1984·Clinical Pharmacology and Therapeutics·S KaukinenH Vapaatalo
Jan 1, 1984·Virchows Archiv. A, Pathological Anatomy and Histopathology·N UedaH Fukuzaki
Aug 1, 1983·Arthritis and Rheumatism·A RozkovecC M Oakley
Jun 1, 1980·Chest·D E Snider, L S Farer
Apr 1, 1956·British Heart Journal·I W CALDWELL, J D AITCHISON

❮ Previous
Next ❯

Citations

Mar 20, 1998·Arthritis and Rheumatism·A TedeschiA Miadonna
Apr 14, 1999·Comprehensive Therapy·H I Palevsky, I Gurughagavatula
Oct 6, 2007·Clinical Reviews in Allergy & Immunology·Ronald A Asherson, Ricard Cervera
May 18, 2005·Clinics in Dermatology·Andreas Katsambas, Christina Stefanaki
Jan 1, 1997·Ryōikibetsu shōkōgun shirīzu·H Ohtani, H Imai
Nov 15, 2001·Joint, Bone, Spine : Revue Du Rhumatisme·L Mouthon, C Agard
Dec 1, 1996·Seminars in Arthritis and Rheumatism·A KatzP Langevitz
Apr 1, 1996·Australian and New Zealand Journal of Medicine·L L WallmanD J Williamson
Feb 7, 2002·Annals of the Rheumatic Diseases·G EspinosaR A Asherson
Jan 1, 1997·Annual Review of Medicine·D B Badesch
Apr 11, 2001·Drugs·C Leighton
Dec 21, 2000·Current Rheumatology Reports·C P Denton, C M Black
Feb 8, 2006·Arthritis and Rheumatism·Janet E PopeAdriana Krizova
Jan 26, 1999·Clinics in Chest Medicine·O A MinaiA C Arroliga
Nov 1, 1996·Rheumatic Diseases Clinics of North America·R M Silver
May 1, 1997·Rheumatic Diseases Clinics of North America·I Gurubhagavatula, H I Palevsky
Feb 28, 2003·Expert Opinion on Investigational Drugs·Sangeeta D Sule, Fredrick M Wigley
Jul 6, 2000·Baillière's Best Practice & Research. Clinical Rheumatology·C P Denton, C M Black
Jan 22, 2015·Current Rheumatology Reports·Stéphane Zuily, Denis Wahl
Apr 28, 2016·Expert Review of Clinical Immunology·Ahlam Al MarzooqiMunther A Khamashta
Apr 23, 2005·The Cochrane Database of Systematic Reviews·N S ParamothayanE H Walters
Mar 25, 1998·Seminars in Cutaneous Medicine and Surgery·J H Stone, F M Wigley
Apr 9, 1999·Medizinische Klinik·R SchmidtI Scharrer
Dec 1, 2008·Expert Review of Respiratory Medicine·Ralf EwertChristian Opitz
Aug 5, 2019·Clinics in Chest Medicine·Maria KokosiSangita Agarwal
Dec 8, 2020·Pulmonary Circulation·Mark ToshnerKurt W Prins
Nov 1, 1996·Rheumatic Diseases Clinics of North America·J E Pope

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.